Treatment of intraocular lymphoma with high-dose Ara-C

Cancer. 1986 Apr 1;57(7):1273-5. doi: 10.1002/1097-0142(19860401)57:7<1273::aid-cncr2820570702>;2-c.


Ocular lymphoma is an uncommon clinical entity with a propensity for intracranial extension. Palliation has been reported following radiotherapy, but the ultimate prognosis is poor, and significant treatment-related morbidity is common. Recent pharmacokinetic studies have suggested that sustained therapeutic drug concentrations are achievable in cerebrospinal fluid after systemic administration of high-dose cytosine arabinoside (Ara-C). These data led the authors to attempt treatment of a case of recurrent ocular lymphoma with high-dose Ara-C. Therapeutic drug levels were documented in intraocular fluids, and prolonged objective regression of tumor was seen. Systemic high-dose Ara-C deserves consideration for the treatment of ocular lymphoma.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cytarabine / administration & dosage*
  • Cytarabine / therapeutic use
  • Eye Neoplasms / drug therapy*
  • Eye Neoplasms / radiotherapy
  • Eye Neoplasms / surgery
  • Female
  • Humans
  • Lymphoma / drug therapy*
  • Lymphoma / radiotherapy
  • Lymphoma / surgery
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Palliative Care


  • Cytarabine